-
21.发明公开Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 审中-公开为程序性死亡-1（PD-1）的人单克隆抗体，并用单独PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
公开(公告)号：EP2439272A3
公开(公告)日：2013-07-31
申请号：EP11178188.6
申请日：2006-05-02
发明人： Srinivasan, Mohan , Wang, Changyu , Selby, Mark, J. , Chen, Bing , Cardarelli, Josephine, M. , Korman, Alan, J. , Huang, Haichun
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
公开(公告)号：EP2383295A1
公开(公告)日：2011-11-02
申请号：EP11166104.7
申请日：2004-12-10
申请人： Medarex, Inc.
发明人： Deshpande, Shrikant , Huang, Haichun , Srinivasan, Mohan , Cardarelli, Josephine, M , Wang, Changyu , Passmore, David , Rangan, Vangipuram, S , Lane, Thomas, E , Keirstead, Hans, S , Liu, Michael, T
CPC分类号： C07K16/24 , A61K2039/505 , C07K14/522 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP- 10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
公开(公告)号：EP2277543B1
公开(公告)日：2015-12-16
申请号：EP10010884.4
申请日：2003-09-05
发明人： Huang, Haichun , Varnum, Brian , Vezina, Chris , Witte, Alison , Qian, Xueming , Martin, Frank , Elliott, Gary
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
-
24.发明授权Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors 有权人抗IFN-γ的中和抗体作为选择性IFN-γ途径抑制剂
公开(公告)号：EP2298811B8
公开(公告)日：2015-02-18
申请号：EP10075518.0
申请日：2003-10-16
IPC分类号： A61K39/395 , C07K16/24
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
-
25.发明公开Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors 有权人类抗-ifn-γ中和抗体作为选择性ifn-γ途径抑制剂
公开(公告)号：EP2298811A3
公开(公告)日：2011-05-18
申请号：EP10075518.0
申请日：2003-10-16
申请人： Amgen Inc.
IPC分类号： A61K39/395 , C07K16/24
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
摘要翻译： 本发明提供了与人干扰素-γ（IFN-γ）相互作用或结合的抗体，以及通过给予药学有效量的IFN-γ抗体治疗IFN-γ介导的疾病的方法。 还提供了使用针对IFN-γ的抗体检测样品中IFN-γ的量的方法。
-
26.发明公开Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors 有权Menschliche抗IFN-γ-中性药物抗炎药治疗IFN-Gamma-Pfadhemmer
公开(公告)号：EP2298811A2
公开(公告)日：2011-03-23
申请号：EP10075518.0
申请日：2003-10-16
申请人： Amgen Inc.
IPC分类号： C07K16/24
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
摘要翻译： 本发明提供了与人干扰素-γ（IFN-3）相互作用或结合的抗体以及通过向IFN-3施用药学有效量的抗体来治疗IFN-3介导的疾病的方法。 还提供了使用IFN-γ抗体检测样品中IFN-3量的方法。
-
27.发明授权Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors 有权人抗IFN-γ的中和抗体作为选择性IFN-γ途径抑制剂
公开(公告)号：EP2298811B1
公开(公告)日：2014-11-26
申请号：EP10075518.0
申请日：2003-10-16
申请人： Amgen Inc. , Medarex, L.L.C.
IPC分类号： A61K39/395 , C07K16/24
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.016 秒)
